Currently Viewing:
Cost-Sharing Roundtable — The Patient Assistance Safety Net: How Many Need Help? How Many Are Helped?
Currently Reading
Addressing Financial Concerns at the Outset to Improve Patient Outcomes
March 02, 2018
Michele McCourt Discusses Growing Financial Hardships for Patients With Cancer
March 03, 2018
M. Kristina Wharton on the Role of Federally Qualified Health Centers
March 04, 2018
Where Does the Existing Healthcare Safety Net Fall Short?
March 05, 2018
Cost-Sharing Roundtable—Introduction
March 05, 2018
Patient Education Vital for Improved Medicare Access, Say Panelists
March 06, 2018
Policy Improvement Areas to Reduce Financial Hardship
March 07, 2018
Dr Todd Yezefski Discusses Using Financial Navigator Programs
March 08, 2018
Ed Haislmaier on Policy Changes That Impact Healthcare Financial Burdens
March 09, 2018
Leigh Purvis Discusses the Burden of High Prescription Drug Costs
March 14, 2018
Ed Haislmaier: Impact of Business Coalitions on Healthcare Costs
March 23, 2018
Dan Klein on Lack of Cost Sharing in Medicare, Drugs Coming Down the Pipeline
March 27, 2018
Michele McCourt Discusses Impact of High Costs for Patients With Cancer
March 27, 2018
Kristina Wharton Analyzes the Health of the Population Using FQHCs
March 29, 2018
Dr Todd Yezefski Discusses the Financial Hardships of Cancer Treatment
March 30, 2018
Leigh Purvis on Out-of-Pocket Costs for Medicare Beneficiaries
March 31, 2018
Ed Haislmaier: Medicare Is "Stuck in a Time Warp"
April 04, 2018
Dan Klein Outlines Policy Changes to Strengthen the Safety Net
April 05, 2018
Kristina Wharton Discusses Services Provided at Federally Qualified Health Centers
April 09, 2018
Dr Todd Yezefski on the Benefits of Financial Navigators in Oncology
April 14, 2018
Ed Haislmaier on Efforts to Lower Drug Costs
April 15, 2018
Michele McCourt on Potential New Therapies for Patients With Cancer
April 17, 2018
Leigh Purvis Outlines the Burdens of High Drug Costs on Medicare Beneficiaries
April 20, 2018
Dan Klein Explains the Need for Patient Assistance Foundations
April 22, 2018

Paul Billings Discusses Balancing Innovative Therapies With Higher Costs

As new therapies come to market, there is the good news that patients are cured or living longer, but it has to be balanced by the bad news that these treatments are far more expensive, said Paul Billings, senior vice president advocacy for the American Lung Association.


As new therapies come to market, there is the good news that patients are cured or living longer, but it has to be balanced by the bad news that these treatments are far more expensive, said Paul Billings, senior vice president advocacy for the American Lung Association.

Transcript

What impact will new, potentially curative, therapies have financially on patients and the healthcare system?

Well there’s great promise for new innovations in diseases like lung cancer, where we’ve seen many new therapies approved in the last couple of years that are not only extending the life, but also improving the quality of life for people with lung cancer. So, we’re hopeful that someday we will see many more cures come into the marketplace.

However, we also know that these medications are coming with extremely high costs. So, it’s a real challenge for the system to balance the need for innovation, the patient demand for hope, with out-of-pocket costs that can be extremely expensive and can really limit the ability of patients to have the benefits of this innovation.

How are the financial hardships facing patients with cancer changing as cancer becomes more of a chronic condition for many?

It’s a good news story: as a cancer becomes a chronic disease for many patients, it means that patients are living longer and living better lives as they are able to manage with targeted therapies, so they don’t have the wide range of adverse side effects that many experience with traditional chemotherapy. But it also means that patients are incurring costs for the rest of their lives.

So, it’s good news—you’re living longer—but the challenge is that it’s expensive. There’s not an easy solution to the situation, but we’re optimistic that we will find cures for lung cancer and other diseases and we hope that that innovation continues, and we hope to navigate the high costs by making improvements to the process.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up